Latest From Biotech Now

The Economist – Biotechnology: Fever Rising

The-Economist-115x76

After speaking with several attendees and speakers at last week’s BIO CEO & Investor Conference, the Economist featured an article this week about the strong performance of biotech equities recently: AS INVESTORS and executives crammed into a New York ballroom for a conference held this week by the Biotechnology Industry Organisation, the mood was jittery. The previous week eight biotech firms had launched initial public offerings in America, together raising more than $500m. In a discussion Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , ,

GM Crop Technology Provides Boost to Developing Country Farmers

Canola-115x76

Millions of farmers around the world continue to choose to plant and replant genetically modified (GM) crop varieties because of their environmental and socio-economic benefits and the important role they play in maintaining food security, according to a new study. The report, Global Status of Commercialized Biotech/GM Crops: 2013, released annually by the International Service for the Acquisition of Agri-Biotech Applications (ISAAA), says a record 18 million farmers in 27 countries are growing biotech crops on Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

National Health Interview Survey: Adult Vaccination Rates Need Boost

Copyright sanofi pasteur

The Centers for Disease Control and Prevention (CDC) recently released immunization coverage estimates from the 2012 National Health Interview Survey (NHIS) for six vaccines routinely recommended for adults including pneumococcal, tetanus and Tdap, Hepatitis A, Hepatitis B, herpes zoster (shingles), and Human papillomavirus (HPV). These data indicate little overall improvement in vaccination coverage among adults from 2011 to 2012. Compared with 2011, modest increases occurred in three vaccines: Tdap, herpes zoster and HPV. However, vaccination Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Business Roundtable: The Reimbursement Landscape under ACA

Capture

As the Affordable Care Act is implemented, reimbursement for life-saving and life-enhancing drugs is one of the most pressing issues facing healthcare stakeholders and decision makers, including patients, payers, providers, and innovative drug developers. BIO hosted a business roundtable discussion on this timely topic yesterday at our 16th Annual BIO CEO & Investor Conference. Moderated by Real Endpoint’s Roger Longman, panelists represented a variety of perspectives: Peter Bach, MD, MAPP, Attending Physician, Memorial Sloan-Kettering Cancer Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

#BIOCEO14: An Optimistic Outlook for 2014

Panel

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining the current capital market for IPOs, where the industry has been and where it’s headed in 2014. The panel unanimously agreed: 2013 was the year of the IPO. In total, 56 healthcare companies priced an IPO; 43 of these were biotech companies. Last year was the strongest IPO year since 2000 and the second strongest in history with over $10 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,